Initial Beneficial Ownership · 3/A

First Tracks Biotherapeutics, Inc.

TRAXNASDAQEQUITYCurrent

Initial Beneficial Ownership

Filed Aug 7, 2026Accepted Aug 7, 2026, 5:11 PM EDTFiling CIK 2091349Accession 0001673528-26-000015

View company →Permanent SEC source ↗

Structured filing — 3/A

form3a-08072026_090846.xml

Open full document ↗

Amendment · This filing reports the amendment as submitted.

Filing details

Report period: 2026-04-20
Original submission: 2026-04-20
Issuer: First Tracks Biotherapeutics, Inc.
Issuer CIK: 0002091349
Trading symbol: TRAX

Reporting owner 1

Name: Faga Daniel
Reporting owner CIK: 0001673528
Relationship: Director · Officer
Officer title: President, CEO
Address: 10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA, 92121

Derivative holdings

Derivative holdings · 1 reported row
Security	Conversion / exercise price	Exercisable	Expires	Underlying security	Underlying shares	Ownership
Performance Stock Unit	0	^[F1]	^[F1]	Common Stock	53,334	D

Table key

D: Direct

Footnotes

F1: The PSUs vest and settle over two years; 50% vests on March 12, 2027 and 50% vests on March 12, 2028, subject to the continuing service of the Reporting Person on each vesting date.↩ 1 ↩ 2

Remarks

This Form 3 Amendment, originally filed on April 20, 2026, is updated to reflect 53,334 performance stock units held by the Reporting Person.

Signature 1

Signed: /s/ Ajim Tamboli, Attorney-in-Fact
Date: 2026-08-07

Company context

We are a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. Our clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which we completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (“RA”), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (“CeD”) and eosinophilic esophagitis (“EoE”), and ANB101, a BDCA2 modulator, in a Phase 1a trial.

Current securities

TRAXNASDAQ · EQUITY · Current

Get the free weekly BCS email.